Seed, Scaffold and Signal in One Cartilage Procedure

Why cartilage fails to repair on its own

Scratch skin and the body sends a rapid-response team: blood vessels deliver clotting factors, immune cells, and fresh repair cells within hours. Articular cartilage — the smooth white tissue lining every joint surface — receives no such response, because it contains no blood vessels at all. Damage it and the emergency team simply never arrives.

That avascularity creates three distinct gaps. First, there are no repair cells at the site; the tissue cannot seed itself. Second, even if a few cells do migrate in from the joint fluid, they find nothing to anchor to — synovial fluid washes them away before they can settle and build. Third, without the right biochemical signals, any cells that do remain lack the chemical instruction to become cartilage-producing chondrocytes; they default instead to scar tissue or nothing at all.

These are not three versions of the same problem. They are three separate biological failures, each requiring a different solution. That logic — one targeted answer per failure mode — is precisely what shapes the NanoACi framework.

Three roles, one biological logic

NanoACi™ — Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique — answers each failure mode with a defined biological role. The shorthand is deliberate: Seed. Scaffold. Signal.

The Seed is Mytocel MSK: autologous micrografts prepared from a small sample of the patient's own auricular cartilage in the same sitting. The Scaffold is ChondroFiller: an injectable, acellular type I collagen matrix that gels in situ, physically retaining the micrografts at the repair site. The Signal is Arthrozheal: autologous platelet-rich fibrin that releases growth factors in a sustained manner to direct chondrogenic activity.

Each component carries its own published evidence base. Combined, they form a single integrated preparation — sampled, processed and delivered in one planned sitting, without external cell culture. The logic is not additive: remove any one role and the remaining two cannot compensate. Without retention, cells wash away. Without cells, the scaffold is inert. Without a signal, cells receive no instruction to build cartilage. Three roles. One procedure.

Seed: autologous cartilage cells prepared chair-side

Living cartilage cells are the irreplaceable core of the repair — without them, no scaffold or signal can rebuild tissue. The Seed component of NanoACi is Mytocel MSK: micrografts prepared from a small sample of the patient's own auricular (ear) cartilage, processed mechanically during the procedure itself, in the same clinical room.

Three 2.5-millimetre punches from the concha of the ear — taken under local anaesthetic — provide the raw material. The donor site heals within a week and sits concealed within the natural fold of the ear. Preparation is mechanical rather than enzymatic or biological: there is no enzyme digestion, no cell culture, and no off-site laboratory stage. The micrografts are ready within the same sitting.

The choice of auricular cartilage is not incidental. Ear cartilage is neural-crest derived and HOX-negative — meaning these cells carry no fixed positional address that locks them to a single tissue identity. Unlike chondrocytes taken from limb cartilage, which carry a spatial programme tied to their origin site, ear-derived cells are environmentally responsive. Transplant model research has shown they read their new surroundings and adopt the identity appropriate to that location; placed within a joint, they are capable of taking on the biological behaviour of joint cartilage.

Because the cells are autologous — drawn from the same patient — there is no immune rejection risk, and the weeks-long wait associated with ex-vivo cell expansion is removed entirely.

Scaffold: the collagen matrix that holds cells in place

ChondroFiller solves the retention problem by arriving as an injectable liquid that gels in situ within minutes, transforming into a three-dimensional collagen mesh that physically locks the micrografts at the defect site.

The chemistry behind that mesh matters. ChondroFiller is manufactured from rat-tail tendon using non-enzymatic weak-acid extraction — a process that leaves the telopeptide end-segments of the collagen molecules intact. Think of telopeptides as the clasps on a necklace: when they are present, adjacent fibres link together naturally, in the same way they would in healthy tissue. Manufacturing methods that use enzymes strip those clasps away, leaving chains that fill space but cannot weave into the body's own matrix architecture. The result is a bioinstructive environment — offering cartilage cells the mechanical and biochemical context they need to build genuine repair tissue — rather than a passive plug.

The scaffold's track record is well established. ChondroFiller holds a CE mark for the gel form (2012) and the injectable liquid form (2013), and has exceeded 20,000 implantations across knee, hip, thumb and wrist applications over more than a decade. Published clinical data report MOCART imaging scores of 70 to 87; MOCART runs from 0 to 100, and scores above 70 are generally indicative of good-to-excellent defect fill on MRI. Weninger et al. (2025) extended its use to end-stage Grade IV knees, recording clinical benefit in that demanding context.

In the NanoACi triad, ChondroFiller's role is to give the Seed somewhere to stay and the Signal somewhere to act — converting a cell suspension into a structured, site-specific repair attempt.

Signal: the growth-factor release that sustains repair

The third preparation is the simplest to picture: blood drawn from the patient's own arm, processed chair-side in a sealed automated system, and returned — within the same sitting — as Arthrozheal, a platelet-rich fibrin concentrate ready to be combined with the other components. No additives, no external material: the Signal is entirely autologous.

What centrifugation produces is not a clear liquid but a fibrin mesh — a gel that concentrates platelets and physically entraps the growth factors they carry. The significance lies in how those factors are then released. Rather than delivering a single bolus that dissipates quickly into the synovial environment, the fibrin structure holds them in reserve, releasing TGF-β, PDGF and related mediators in a sustained, controlled manner over the critical early repair window. Lundquist et al. (2008) documented PRF's growth-factor profile and its stimulating effect on fibroblast proliferation and type I collagen synthesis; Ågren et al., writing in Vox Sanguinis (2014), confirmed its sustained-release kinetics; and Peset (2020) described clinical application of PRF in the knee setting.

Professor Paul Lee uses the analogy of a slow-release fertiliser: the fibrin delivers its biochemical instruction gradually, precisely when the seeded chondrogenic cells most need the directive to begin synthesising cartilage matrix. Cells anchored within even a well-constructed scaffold will remain metabolically quiet without that sustained chemical cue — it is what converts physical retention into active biological repair.

One planned sitting: how the three components come together

The three components do not exist independently for long. In a single planned sitting — a clinic room, not an operating theatre, with the patient awake throughout — the auricular biopsy is taken under local anaesthetic, the blood draw is centrifuged into PRF, and the collagen scaffold is prepared. The three elements are combined and delivered by needle to the cartilage defect site. No external laboratory stage intervenes; no second admission is scheduled. Three biological roles. One planned procedure.

That procedural simplicity is structural, not incidental. Traditional autologous chondrocyte implantation (ACI) and its matrix-supported variant MACI require two hospital admissions, two anaesthetics, a laboratory cell-culture stage lasting several weeks, and months of protected recovery to follow. NanoACi removes the laboratory entirely: auricular micrografts require no expansion culture — mechanical preparation happens at the point of care — and the collagen scaffold and PRF are ready within the same session. For suitable patients, this constitutes a non-arthroscopic lane to cartilage repair rather than a challenge to established surgical care.

Specialist involvement remains integral throughout. Image-guided needle delivery is the access route; case selection, preparation sequencing and structured follow-up are built into the protocol. The technique is designed around the surgeon's continued judgement, not around removing it.

Where imaging shows that mechanical correction is also needed, the STACi variant adds a Structure stage — alignment, stabilisation or defect preparation — before Seed, Scaffold and Signal are applied arthroscopically within the same operative plan.

Combined-protocol outcomes are being prospectively collected through the NanoACi 100 programme, a commitment to measurement built into the protocol from the outset. Each component carries its own published evidence base; NanoACi 100 is designed to establish how the three-part preparation performs as a unified whole.